Truveta Public-Source Startup Diligence Report
Proceed only to confirmatory diligence. The upside thesis depends on differentiated, durable health-system data access and trusted real-world evidence/AI workflows; the risk case is that public scale claims mask concentrated data supply, unproven unit economics, costly regulatory/privacy controls, AI validation gaps and complex strategic-investor rights.
Truveta Public-Source Startup Diligence Report
Truveta appears to be a credible, active late-stage healthcare-data unicorn with public evidence of substantial financing, health-system roots, broad data/product positioning, strategic partners and active leadership. Public diligence is insufficient to underwrite revenue quality, customer economics, privacy/security controls, regulatory-grade evidence, AI safety, IP defensibility, legal exposure or cap-table economics.
The company’s value proposition depends on large-scale de-identified clinical, claims, imaging, mortality, multiomics and genetic-linkage data. Expert determinations, re-identification testing, BAAs, opt-out/consent logic and incident response are mission-critical and not public.
Diligence request: Specialist privacy/security counsel should review expert determinations, BAAs/DUAs, consent/opt-out governance, incident logs, security audits and re-identification testing.
Truveta’s differentiation appears tied to participating health systems and data feeds. Public logos do not disclose contribution percentages, withdrawal rights, exclusivity, renewal terms or concentration.
Diligence request: Request data-supplier contracts, contribution metrics, termination rights, renewal calendar, exclusivity constraints and concentration analysis.
Company materials assert FDA-aligned, regulatory-grade, audit-ready evidence, but public materials do not prove data lineage, missingness, validation, audit results or actual regulatory acceptance.
Diligence request: Review quality management system, provenance/audit trails, data curation SOPs, external audits, validation studies and regulatory submission examples.
Truveta Intelligence’s public AI/natural-language positioning could create clinical or research reliance risk if outputs are inaccurate, biased, stale or used beyond intended scope.
Diligence request: Request model cards, validation datasets, human-review workflow, hallucination controls, safety boundaries, audit logs and customer incident history.
CB identifies Truveta among EHR integrators/health data analytics and adjacent RWE/clinical-trials-tech companies. Pricing pressure, data exclusivity, evidence quality and buyer trust will drive differentiation.
Diligence request: Run buyer/reference calls and win/loss analysis against HealthVerity, TriNetX, OM1, Flatiron, Komodo, Atropos, Dandelion and others.
Public sources disclose financing and logos, not ARR, bookings, margins, churn, NRR, backlog, AR aging, CAC/payback, usage depth, discounts or product/customer profitability.
Diligence request: Request audited financials, KPI pack, cohort retention, top-customer ARR, gross margin, CAC/payback, backlog and AR aging.
Headline $515M raised and unicorn status do not reveal ownership, liquidation preferences, participation, anti-dilution, debt, warrants, option pool or pay-to-play provisions.
Diligence request: Request fully diluted cap table, financing documents, investor rights, option/warrant schedule, debt instruments and waterfall model.
CB reports 9 patents, but public evidence does not establish claim scope, ownership, assignments, FTO, trade-secret controls, open-source exposure or data-rights defensibility.
Diligence request: IP counsel should review patent docket, assignments, invention agreements, open-source inventory, trade secrets and FTO.
Public evidence supports Truveta’s private-unicorn status, $515M total raised and a $320M 2025 round, but audited financials, ARR, margins, cash, debt, forecast quality and cap-table terms are not public.
not publicly verifiable confidence: high
No audited financial statements, management accounts, sales/gross-profit breakdowns, backlog or AR aging were public. Public sources provide financing and headcount proxies only.
| metric | public signal | verification status | why it matters | private data request |
|---|---|---|---|---|
| ARR/revenue/bookings | Not disclosed in accessible public sources. | not_publicly_verifiable | Determines valuation support and sales productivity. | Audited financials, ARR bridge, bookings, NRR/churn and deferred revenue. |
| Customer/subscriber monetization | Truveta Intelligence available to existing Truveta Data subscribers per CB/GeekWire excerpt; no subscriber count or price. | partially_verified | Could imply expansion motion, but revenue conversion unknown. | Subscriber count, ACV, expansion rate, pricing/discounting and module attach. |
| Headcount proxy | CB/GeekWire excerpt says more than 400 employees. | verified | Expense base and burn proxy, not revenue proof. | Payroll, headcount by function/location, hiring plan and cash runway. |
partially verified confidence: medium
Truveta has public funding/valuation anchors but no public operating plan, growth model, pricing assumptions, capex/working-capital forecast or external-financing assumptions.
| date | round | amount | participants | post money or valuation | verification status | diligence caveat |
|---|---|---|---|---|---|---|
| 2021-07-13 | Series A announcement | $95M | Company says three health-provider members joined; full investor list not disclosed in excerpt | Not disclosed | verified | Request financing documents, preferences and ownership by investor. |
| 2025-01-13 | Series C / last raised | $320M | CB/GeekWire excerpt names Regeneron, Illumina and 17 health systems | Above $1B valuation per CB/GeekWire excerpt; exact valuation field hidden | verified | Request term sheet, cap table, liquidation preferences and valuation bridge. |
| As of accessed date | Total capital raised | $515M total raised | Providence, Advocate Health, Illumina, Regeneron, Trinity Health and 11 more per CB FAQ | Not publicly disclosed beyond above-$1B statement | verified | Reconcile all rounds, debt, SAFEs/notes, warrants and secondary sales. |
partially verified confidence: medium
Public investor and partner names are visible, but share counts, ownership, preferences, options/warrants, debt and off-balance-sheet liabilities are private.
| stakeholder | public position | evidence | diligence caveat |
|---|---|---|---|
| Health-system owners/investors | Truveta has been described as health-provider-led/owned and governed by 17 providers in 2021; CB names Providence, Advocate Health, Trinity Health among investors. | Microsoft announcement and CB investor FAQ. | Confirm current equity ownership, governance rights, data-supplier rights and exit vetoes. |
| Strategic life-science/technology investors | CB/GeekWire excerpt names Regeneron and Illumina in 2025 round; Genome page shows Regeneron/Illumina logos. | CB and Truveta Genome Project page. | Confirm commercial rights, data access, ROFR/ROFN, information rights and conflicts. |
| Employees/options/warrants/debt | Not publicly disclosed. | No public share-count, option-pool, warrant or debt details found. | Request fully diluted cap table, option schedule, debt instruments and waterfall. |
partially verified confidence: medium
The public financing history includes a 2021 $95M Series A and 2025 $320M round, but tax positions, accounting policies and detailed round terms are not public.
Public materials support a broad Truveta Data/Studio, Intelligence, Live Link and Genome product narrative, but pricing, adoption, validation, quality metrics and implementation economics remain private.
partially verified confidence: medium
Truveta publicly markets multimodal daily updated de-identified clinical data, AI Intelligence, Live Link and Genome initiatives; product maturity, adoption, margin and safety/quality validation are not public.
| product | audience | key features | verification status | main diligence question |
|---|---|---|---|---|
| Truveta Data / Truveta Studio | Life sciences, public health, healthcare and academics | De-identified EHR, claims, devices, images, SDOH, mother-child, multiomics and mortality data with analytics/research workflows. | partially_verified | Validate data quality, data rights, refresh SLA, coverage/missingness and pricing. |
| Truveta Intelligence | Researchers and healthcare leaders | AI/natural-language question answering, methodology verification, answers in minutes. | partially_verified | Validate model safety, accuracy, intended use, auditability and customer adoption. |
| Truveta Live Link | Life-science organizations | Links proprietary data to daily updated EHR for prospective/regulatory-grade evidence and real-time follow-up. | partially_verified | Validate linkage accuracy, consent, data storage, customer economics and regulatory acceptance. |
| Truveta Genome Project | Researchers and participating health systems/life-science partners | Links de-identified genetic data to de-identified medical records. | partially_verified | Validate consent, enrollment, sequencing costs, data-rights allocation and IRB/ethics governance. |
| offering | public pricing | likely metric to request | risk if unverified |
|---|---|---|---|
| Truveta Data / Studio subscription | No public price found. | ARR/ACV by customer segment, data-module attach, user seats, usage fees and discounts. | Cannot assess gross margin, budget fit or expansion economics. |
| Truveta Intelligence | Available to existing Truveta Data subscribers per CB/GeekWire excerpt; no price disclosed. | Attach rate, incremental ACV, usage caps and AI inference cost. | AI feature may be costly or defensive rather than monetized. |
| Live Link / prospective research | No public price found. | Project fees, recurring storage/linkage fees, data-ingestion costs and margin. | Large custom services burden could compress margin. |
| dependency | role in product | public evidence | key control to test |
|---|---|---|---|
| Health-system EHR and care-setting feeds | Core longitudinal clinical record source. | Homepage claims all care settings, daily updates and built with US health systems. | Data-use rights, termination rights, feed SLAs, missingness and normalization quality. |
| Claims/devices/images/SDOH/multiomics/mortality | Adds breadth for outcomes, safety and multimodal evidence. | Homepage lists modalities; Genome page describes linked genetic data. | Source provenance, patient matching, de-identification, consent and re-identification risk. |
| AI/natural-language models and methodology verification | Truveta Intelligence user interface and evidence synthesis. | Intelligence page says ask questions and verify methodology. | Model validation, bias, error handling, audit logs, intended-use guardrails and clinical safety review. |
Public logos and partner announcements indicate a substantial health-system/life-science ecosystem, but customer revenue concentration, churn, contract status, data-supplier economics and severed relationships are not publicly verifiable.
partially verified confidence: medium
Public logos include health systems and life-science organizations, but top 15 customers, applications, purchase timing and product ownership are private.
| organization | public context | verification status | diligence caveat |
|---|---|---|---|
| Providence; Trinity; Tenet; Advocate; CommonSpirit; Northwell; AdventHealth; Baptist Health; Baylor Scott & White; Bon Secours Mercy; HealthPartners; Henry Ford; Inova; MedStar; Memorial Hermann; Ochsner and others | Homepage lists health-system logos under built with US health systems. | verified for public display | Confirm current membership, data contribution, contract term, termination rights and revenue/data-dependency weight. |
| Boston Scientific; Moderna; Boehringer Ingelheim; SK Life Science; Medcomp and others | Homepage says trusted by leading life science, public health and healthcare organizations. | verified for public display | Confirm customer status, ACV, use case, renewal, data-use limits and referenceability. |
| Existing Truveta Data subscribers | CB/GeekWire excerpt says Truveta Intelligence is available to existing Truveta Data subscribers. | partially_verified | Subscriber count, expansion potential and usage are not public. |
partially verified confidence: medium
Strategic relationships with Microsoft, health-system members and genomics/life-science participants are public, but economics, exclusivity and governance rights are private.
| partner | public evidence | strategic value | private gap |
|---|---|---|---|
| Microsoft | 2021 announcement says platform built on Azure and Microsoft helps bring platform to market globally. | Cloud/security/compliance and GTM leverage. | Current contract, spend commitments, outage/SLA, margin impact and data residency. |
| Regeneron and Illumina | CB/GeekWire excerpt names round participants; Genome page shows Regeneron/Illumina logos. | Life-science credibility, genomics linkage and potential customer/investor alignment. | Commercial rights, sequencing economics, exclusivity, conflicts and data rights. |
| Health-system member/owner network | Microsoft announcement says provider-led, owned and governed by 17 U.S. health providers; homepage lists many systems. | Differentiated data access and trust. | Contribution concentration, withdrawal rights, governance vetoes and renewals. |
not publicly verifiable confidence: high
No customer revenue, concentration, NRR, churn, usage or receivables data was public.
not publicly verifiable confidence: low
No severed customer, partner or supplier relationship was found in accessible public sources. This is inconclusive, not a clean bill of health.
partially verified confidence: medium
Microsoft Azure, health-system data feeds and genomic/proprietary data inputs are public dependency categories, but purchase amounts and agreements are private.
| supplier or input | public evidence | concentration risk | diligence request |
|---|---|---|---|
| Microsoft Azure | Microsoft partnership says Truveta chose Azure as cloud platform. | Cloud costs, outage exposure, vendor lock-in and compliance dependency. | Cloud contracts, spend commitments, uptime history, DR/BCP, security reports and margin sensitivity. |
| Health-system source data | Homepage says built with US health systems; 2021 announcement/provider network. | Loss of a major system or feed quality issue could impair data coverage and customer value. | Data supplier contracts, data quality scorecards, renewal/termination rights and concentration. |
| Genomic/sequencing and proprietary customer data inputs | Genome Project and Live Link pages. | Consent, data-rights, quality and vendor economics could constrain growth. | Consent, sequencing/vendor contracts, data rights and project margins. |
CB places Truveta among EHR integrators, health data/analytics and adjacent RWE/clinical-trials-tech competitors. Truveta’s claimed moat is data breadth, provider governance and regulatory-grade/AI workflows, but buyer win/loss and pricing pressure are private.
partially verified confidence: medium
Competitive pressure is high across health-data, RWE, clinical-trials-tech, EHR integration and clinical AI. Public sources identify the arena but do not prove market share or win rates.
| company | public overlap | differentiator or gap | source basis |
|---|---|---|---|
| Truveta | Target company. | Claims health-system ownership, 1 in 3 Americans, daily updated data and regulatory-grade evidence; verify economics and quality. | Truveta and CB public pages. |
| Atropos Health / Dandelion / 3Aware / Medicom / Tasq.ai | CB lists as competitors/alternatives. | Need buyer-reference and product-depth comparison; public details limited in this run. | CB profile competitor list. |
| HealthVerity, TriNetX, OM1, Tempus, Verana, ConcertAI, Clarify, Aetion, Syapse, COTA | CB clinical-trials-tech market map includes Truveta among these companies. | Compare data breadth, regulatory acceptance, trial recruitment, pricing and pharma penetration. | CB research snippet. |
| EHR/integration incumbents such as Veradigm, Infor, Innovaccer | CB names Truveta Highflier among EHR integrators including these companies. | Assess whether Truveta is a data network, analytics platform or interoperable workflow vendor in buyer perception. | CB ESP snippet. |
| axis | competitive pressure | evidence or gap | diligence test |
|---|---|---|---|
| Data breadth and freshness | High; competitors can own different datasets or payer/pharma relationships. | Homepage claims; coverage/missingness not audited publicly. | Benchmark coverage, refresh, missingness, linkage accuracy and data-rights durability. |
| Regulatory-grade evidence and auditability | High for life-science buyers and regulatory submissions. | Public claim only; no audit evidence reviewed. | Review QMS, SOPs, submission examples and external audits. |
| AI/user workflow | High; clinical AI/RWE vendors can package similar workflows. | No public model validation or adoption metrics. | Run side-by-side user tasks, error testing and buyer ROI references. |
| Trust/governance | Medium/high; governance can be a moat or a constraint. | Governance terms and data withdrawal rights private. | Review governance documents and data-supplier contracts. |
Public GTM appears enterprise/direct, health-system network-driven and partner-assisted, targeting life sciences, public health, healthcare and academics. Public sources do not reveal sales productivity, CAC, payback, pipeline, quotas or marketing budget sufficiency.
partially verified confidence: medium
Truveta positions itself as a data/intelligence/evidence platform for multiple healthcare ecosystem segments; PR and product pages support awareness but not conversion.
| channel | target segment | verification status | gap |
|---|---|---|---|
| Direct enterprise data subscription/demo motion | Life-science, public-health, healthcare and academic organizations. | partially_verified | Pipeline, ACV, sales cycle, pricing and conversion not public. |
| Health-system owner/member network | Health systems as data partners, customers and governance stakeholders. | verified for public positioning | Member economics, revenue share, exclusivity and renewal terms private. |
| Strategic technology/life-science partnerships | Global platform distribution and genomics/life-science research. | partially_verified | Current partner contribution, co-sell economics and conflicts private. |
| signal | public message | source ids | diligence readthrough |
|---|---|---|---|
| Series A/provider expansion announcement | More than 15% of U.S. patient care and $95M Series A. | SRC-010 | Early supply-side network growth; needs current member retention proof. |
| Microsoft strategic partnership | Azure/AI platform, global market support, privacy-preserving techniques. | SRC-009 | Credibility and infrastructure support; check current terms and dependency. |
| Regulatory-grade, Live Link, Genome and Intelligence product pages | Regulatory-grade RWE, proprietary data linkage, genomics and AI answers. | SRC-005/SRC-006/SRC-007/SRC-008 | Expansion product surface; require actual adoption and paid conversion. |
partially verified confidence: medium
Public logos and subscriber references do not disclose relationship trends, expansion pipeline or future growth prospects with major customers.
partially verified confidence: medium
New business likely comes from enterprise data subscriptions, partner/network leverage and product expansion, but funnel data is private.
not publicly verifiable confidence: high
Sales compensation, quota, sales cycle, ramp, attainment and hiring plan are not public.
| item | risk if missing | requested private artifact |
|---|---|---|
| Sales compensation and quota | Cannot assess productivity, attainment quality or hiring plan. | Quota model, comp plans, rep tenure/attainment and hiring plan. |
| Sales cycle and pipeline | Regulated enterprise sales may be long, lumpy and proof-of-value intensive. | Pipeline by stage, conversion, average sales cycle, proof-of-value metrics and forecast accuracy. |
| CAC/payback and implementation capacity | Services/data-onboarding load could depress gross margin and growth efficiency. | CAC/payback, implementation staffing, support load, onboarding cycle and gross margin by product. |
not publicly verifiable confidence: high
Budget sufficiency cannot be assessed without sales/marketing spend, pipeline and operating plan.
Public R&D signals are strong across data normalization, regulatory-grade evidence, AI Intelligence, Live Link and Genome initiatives, but roadmap timing, development costs, validation, staffing and critical dependencies are private.
partially verified confidence: medium
Leadership page shows technical and clinical leadership roles; R&D strategy, team size, budget and major activities are only partly visible through product pages.
| name or role | public background or signal | verification status | private gap |
|---|---|---|---|
| Terry Myerson | Leadership page says CEO Terry Myerson joined the mission in March 2020; CB notes former Microsoft Windows and Devices EVP. | verified | Current employment agreement, equity, key-person risk and succession plan. |
| Jay Nanduri | Leadership page lists CTO/co-founder role. | verified for role display | Engineering org, platform roadmap, hiring/retention and critical dependencies. |
| Ryan Ahern, MD, MPH | Leadership page lists CMO/co-founder role. | verified for role display | Clinical governance, safety review, medical advisory process and regulatory evidence leadership. |
| Deb Nielsen and broader leadership | Leadership page lists Chief People Officer and other roles. | partially_verified | Full org chart, R&D headcount, attrition and hiring plan. |
partially verified confidence: medium
Pipeline signals include Intelligence, Live Link, Genome Project, regulatory-grade evidence capabilities and patent activity; cost, timing, validation and regulatory acceptance are private.
| project | evidence | next milestone gap | risk |
|---|---|---|---|
| Truveta Intelligence | AI/natural-language answers and methodology verification. | Paid adoption, model validation, usage, customer ROI and roadmap. | AI safety and monetization risk. |
| Regulatory-grade evidence / Live Link | Quality/provenance/audit-ready claims and proprietary-data linkage. | Regulatory acceptance, external audits, project pipeline and development cost. | Regulatory-grade claim proof and implementation burden. |
| Truveta Genome Project | Linked de-identified genetic and medical records; partner logos. | Enrollment, consent, sequencing cost, data rights and research uptake. | Privacy/consent, genomics ethics and economics. |
| asset or signal | potential relevance | verification status | diligence request |
|---|---|---|---|
| 9 filed patents | May protect data normalization, privacy and health-informatics workflows. | partially_verified | Direct USPTO patent list, assignments, claim charts and prosecution status. |
| Systems and methods for data normalization | Data normalization could be core to integrating EHR sources. | partially_verified | Review claims, assignees, inventors, continuations and FTO. |
| Trade secrets/data rights/model assets | Likely more important than patents for moat. | not_publicly_verifiable | Trade-secret controls, data-rights contracts, model governance and open-source/license inventory. |
Public pages support an experienced leadership team and more-than-400-employee scale signal, but exact org chart, headcount by function/location, compensation, equity, turnover and employee-relations matters are private.
partially verified confidence: medium
Public leadership chart is available at executive level; full management layers, board/governance reporting and functional org chart are private.
| name | public evidence | tenure signal | diligence request |
|---|---|---|---|
| Terry Myerson | Leadership page and CB profile. | Joined mission in March 2020 per leadership page. | Employment agreement, equity, board role and succession/key-person plan. |
| Jay Nanduri | Leadership page image/role listing. | Co-founder role publicly listed; exact start date not independently verified. | Technical org chart, retention terms and critical-architecture ownership. |
| Ryan Ahern, MD, MPH | Leadership page image/role listing. | Co-founder role publicly listed; exact start date not independently verified. | Clinical governance, safety review ownership and regulatory-evidence role. |
| Deb Nielsen | Leadership page image/role listing. | Role publicly listed; exact tenure not captured. | Hiring plan, HRIS, compensation and attrition data. |
partially verified confidence: medium
CB/GeekWire excerpt gives a more-than-400-employee anchor and careers page is active, but history/projection by function/location is not public.
| metric or signal | source | verification status | private request |
|---|---|---|---|
| Total employees | CB Insights profile | partially_verified | Current HRIS headcount by employee/contractor, function, location and manager. |
| Hiring/activity signal | Truveta careers page | verified for page existence | Open roles, accepted offers, attrition, recruiting funnel and hiring budget. |
| Functional mix | Leadership page | not_publicly_verifiable | Function/location headcount history and forecast. |
partially verified confidence: medium
Senior management biographies are publicly summarized by role, but detailed employment history, tenure, equity, references and background checks are private.
not publicly verifiable confidence: high
No executive compensation, employment agreement or benefit-plan detail was public.
| area | verification status | risk | request |
|---|---|---|---|
| Executive employment/compensation | not_publicly_verifiable | Key-person and retention economics unknown. | Employment agreements, severance/change-of-control, option grants and retention plans. |
| Incentive stock plan/option pool | not_publicly_verifiable | Dilution, retention and employee morale risk. | Plan documents, grant schedule, vesting, 409A and option pool reserve. |
| Employee relations/turnover | inconclusive | Hidden attrition or disputes could impair R&D and customer delivery. | Attrition reports, employee-relations logs, engagement survey and litigation/claims history. |
not publicly verifiable confidence: high
Incentive stock plans and option-pool details are not public.
inconclusive confidence: low
No significant employee-relations problem was found in accessible public sources, but this is inconclusive.
not publicly verifiable confidence: high
Turnover data and retention/benefit plans are not public.
Privacy/de-identification, data rights, regulatory-grade evidence claims, AI governance, IP ownership and contracts are the core legal matters. No public lawsuits or regulatory actions were found in accessible sources, but legal/regulatory searches were limited and require counsel.
inconclusive confidence: low
No pending lawsuits against Truveta were found in accessible public sources; this is an inconclusive public-source screen.
| matter | public status | evidence strength | next step |
|---|---|---|---|
| Pending lawsuits against company | No specific pending case found in accessible sources. | low/inconclusive | Counsel to run PACER, Washington state court, county, arbitration and regulatory searches. |
| Privacy/security incident litigation | No public incident litigation found in accessible sources. | low/inconclusive | Request incident register, claims history, cyber notices and insurance correspondence. |
inconclusive confidence: low
No company-initiated litigation was found in accessible public sources; direct docket searches remain required.
| matter | public status | evidence strength | next step |
|---|---|---|---|
| Company-initiated litigation | No public company-initiated litigation found in accessible sources. | low/inconclusive | Counsel to run court and arbitration searches; request legal-matter schedule. |
| IP enforcement/licensing disputes | No public IP enforcement matter found in accessible sources. | low/inconclusive | Request IP litigation/opposition schedule and licensing disputes. |
partially verified confidence: medium
Environmental risk appears low for a software/data company, but employee safety, privacy/security operations and new privacy/AI regulations require review.
| area | status | risk | diligence request |
|---|---|---|---|
| HIPAA/de-identification/privacy | partially_verified / requires artifact review | Re-identification, consent/opt-out, contractual and regulatory exposure. | Expert determinations, BAAs/DUAs, privacy impact assessments, incident logs, OCR/FTC correspondence. |
| Regulatory-grade RWE and AI | partially_verified | Claims may exceed audited capability or be used beyond intended scope. | QMS, validation, audit trails, regulatory submissions, model cards and safety controls. |
| Material contracts | not_publicly_verifiable | Termination, exclusivity, data-rights, indemnity and revenue-share exposure. | Customer, data-supplier, cloud, investor, genomic and strategic partner agreements. |
| Insurance coverage | not_publicly_verifiable | Cyber, E&O, D&O, clinical/research and privacy liabilities may exceed coverage. | Insurance policies, limits, exclusions, claims history and broker loss runs. |
partially verified confidence: medium
CB reports 9 patents and one data-normalization grant, but direct IP docket, assignments, trademarks, copyrights, licenses and FTO are not verified.
| asset | status | public evidence | diligence request |
|---|---|---|---|
| 9 filed patents | Filed patents per CB; direct patent databases not verified | CB says Truveta has filed 9 patents. | Direct USPTO/WIPO docket, assignments, claims, continuations and prosecution history. |
| Systems and methods for data normalization | Grant per CB table; application 2022-11-08, grant 2025-12-30 | CB table title/topics/status. | Verify patent number, assignee, inventors, claims and maintenance status. |
| Software, models, data dictionaries and source code | Not public | Product pages imply proprietary platform but no source-code/license inventory. | Open-source inventory, assignment agreements, model/data licenses and trade-secret controls. |
not publicly verifiable confidence: high
Insurance policies, limits, exclusions and claims history are not public. Cyber/privacy, E&O, D&O and clinical/research liability coverage are key.
not publicly verifiable confidence: high
Material contracts likely include health-system/data-supplier agreements, customer subscriptions, Microsoft cloud/partnership, investor rights, Genome Project, Live Link and privacy/data-use agreements; terms are private.
inconclusive confidence: medium
No regulatory agency problems were found in accessible public sources, but privacy, FDA/RWE, AI, data-use and consumer-health/privacy rules require specialist review.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Truveta is a 2020-founded Bellevue healthcare-data company listed by CB Insights as Series C/Alive, with $515M total raised and a $320M last round; CB/GeekWire excerpts describe a January 2025 round above $1B valuation and more than 400 employees. | verified high | SRC-001SRC-002 |
| EC-002 | Truveta publicly claims its data platform covers 1 in 3 Americans, all care settings, daily updates, more than 10 years of history, and modalities including EHR, closed claims, devices, images, SDOH, mother-child, multiomics and mortality. | verified medium | SRC-001SRC-003 |
| EC-003 | Truveta publicly presents a broad health-system and customer ecosystem, including US health-system member logos and life-science/public-health/healthcare customer logos. | verified medium | SRC-001SRC-003 |
| EC-004 | Truveta markets use cases across discovery, therapy adoption, safety, outcomes research, clinical trials and healthcare optimization for life-science, public-health, healthcare and academic users. | verified medium | SRC-001SRC-003 |
| EC-005 | Truveta Intelligence is publicly positioned as an AI/natural-language tool that lets users ask questions and verify methodology, with answers in minutes. | partially verified medium | SRC-002SRC-005 |
| EC-006 | Truveta claims regulatory-grade EHR data for more than 130M patients and states its standards address FDA-aligned data quality, provenance and audit-ready controls. | partially verified medium | SRC-006 |
| EC-007 | Truveta Live Link publicly claims to link life-science proprietary data to daily updated EHR data for prospective, regulatory-grade evidence using expert determination and integrated storage. | partially verified medium | SRC-007 |
| EC-008 | The Truveta Genome Project is publicly described as linking de-identified genetic data to de-identified medical records, with partner logos including Illumina, Regeneron Genetics Center, Microsoft and health systems. | partially verified medium | SRC-008 |
| EC-009 | Microsoft and Truveta announced a 2021 strategic partnership to build on Azure and apply AI, with Truveta described as provider-led, owned and governed by 17 U.S. health providers. | verified medium | SRC-009 |
| EC-010 | Truveta announced a $95M Series A in July 2021 while adding Baylor Scott & White, MedStar and Texas Health Resources and claiming representation of more than 15% of U.S. patient care. | verified medium | SRC-010 |
| EC-011 | Truveta publicly emphasizes patient privacy, re-identification prevention, Safe Harbor versus Expert Determination, and advanced de-identification algorithms. | partially verified medium | SRC-011 |
| EC-012 | HHS OCR guidance states HIPAA de-identification can be satisfied through Expert Determination or Safe Harbor and defines PHI broadly. | verified high | SRC-012 |
| EC-013 | Truveta leadership materials identify CEO Terry Myerson and a leadership team with AI, health and data expertise, including CTO, CMO and CPO roles. | verified medium | SRC-004 |
| EC-014 | Truveta careers page was active and describes a mission around regulatory-grade data and analytics, indicating ongoing operating activity and hiring/recruiting presence. | verified medium | SRC-013 |
| EC-015 | CB Insights states Truveta has filed 9 patents and lists a data-normalization patent application dated 2022-11-08 with grant date 2025-12-30. | partially verified medium | SRC-002 |
| EC-016 | CB Insights positions Truveta in EHR integrators/health data analytics and lists competitors and adjacent RWE/clinical-trials-tech companies. | verified medium | SRC-002 |
| EC-017 | Public sources reviewed do not disclose audited financial statements, ARR, revenue growth, margins, cash, debt, valuation bridge, share counts, preferences, option pool or warrants. | not publicly verifiable high | SRC-001SRC-002SRC-003 |
| EC-018 | Public logos and subscriber references do not disclose top-customer revenue concentration, ARR, churn, NRR, renewal status, customer acquisition costs, sales cycle, pricing or customer-level profitability. | not publicly verifiable high | SRC-002SRC-003SRC-005 |
| EC-019 | Public Truveta AI and regulatory-grade claims do not include model validation reports, clinical-safety boundaries, audit evidence, model cards, bias/fairness testing, hallucination controls, or post-market monitoring metrics. | not publicly verifiable high | SRC-005SRC-006SRC-007 |
| EC-020 | No pending litigation, company-initiated litigation, regulatory agency action, insurance coverage, material contracts or employment-relations problems were found in accessible public company/CB sources; direct legal-registry, FDA and patent pages were partially blocked, so this is not a clean legal clearance. | inconclusive low | SRC-002SRC-012SRC-014 |
| EC-021 | Truveta GTM appears enterprise/direct and partner-assisted, targeting life sciences, medical devices, public health, healthcare systems and academics, with Microsoft as a strategic cloud/AI partner. | partially verified medium | SRC-003SRC-009 |
| EC-022 | Public scale signals include more than 400 employees from CB/GeekWire excerpt and active careers/leadership pages, but function, location, hiring plan and attrition are not public. | partially verified medium | SRC-002SRC-004SRC-013 |
| EC-023 | Public R&D/product pipeline signals include Truveta Intelligence, Live Link, Genome Project, regulatory-grade evidence expansion and patent filings, but development cost, roadmap dates and critical-path dependencies are private. | partially verified medium | SRC-005SRC-006SRC-007SRC-008SRC-002 |
| EC-024 | Truveta’s business model concentrates regulated health-data governance risk because it combines large-scale de-identified EHR, claims, images, devices, multiomics, mortality and genetic-linkage data under HIPAA de-identification frameworks. | verified high | SRC-003SRC-008SRC-011SRC-012 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.